Anne-Marie discusses how big pharma companies like Eli Lilly are innovating with new drugs and manufacturing processes, creating a moat against generics. She highlights the strategic moves in healthcare, drawing parallels to tech industry dynamics, and questions the impact of government regulations on the industry's growth and investment strategies.
